Supriya Lifescience IPO
Supriya Lifescience IPO — date, price band, lot size & details 2021
Supriya Lifescience listed on 28 Dec 2021 at ₹421, 53.6% above the ₹274 issue price.
Supriya Lifescience makes active pharmaceutical ingredients and is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India. Its total income was Rs 396.22 crore in FY2021.
Stock price
Supriya Lifescience is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 November.
- Open 16 Dec 2021
- Close 20 Dec 2021
- Allotment 23 Dec 2021
- Refund/credit 24 Dec 2021
- Listing 28 Dec 2021
Issue summary
The terms of the offer, as filed.
| IPO Dates | 16 to 20 Dec, 2021 |
|---|---|
| Price Band | ₹265 – ₹274 |
| Face Value | ₹2 |
| Lot Size | 54 Shares |
| Issue Size | ₹700 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,796 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 54 shares at the ₹274 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 54 | ₹14,796 |
| Retail (max) | 13 | 702 | ₹1,92,348 |
| S-HNI (min) | 14 | 756 | ₹2,07,144 |
| S-HNI (max) | 67 | 3,618 | ₹9,91,332 |
| B-HNI (min) | 68 | 3,672 | ₹10,06,128 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Profit after tax rose from Rs 39.42 crore in FY2019 to Rs 123.83 crore in FY2021.
- 02Total income rose from Rs 285.86 crore in FY2019 to Rs 396.22 crore in FY2021.
- 03EBITDA was Rs 178.15 crore in FY2021, a margin of about 45% of total income.
- 04The pre-issue P/E was 16.19 at the upper band of Rs 274, based on EPS of Rs 16.92.
- 05It exported to 86 countries and was the largest Indian exporter of two APIs.
Risks · 5
- 01Rs 500.00 crore of the Rs 700 crore issue was offer for sale by the promoter, so most of the money did not reach the company.
- 02A few products drive a large share of revenue, such as Chlorpheniramine Maleate and Ketamine Hydrochloride, among its 38 APIs.
- 03Its main plant in Maharashtra makes most products, so a local disruption could hit output. Reactor capacity is 547 KL a day.
- 04Exports to 86 countries add currency and foreign regulatory risk.
- 05Promoter holding fell from 99.98% before the issue to 68.24% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Supriya Lifescience offer document.
| Metric | 30 Sep 2021 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|
| Assets | 504.10 | 445.82 | 336.43 | 253.05 |
| Total Income | 230.06 | 396.22 | 322.71 | 285.86 |
| Profit After Tax | 65.96 | 123.83 | 73.40 | 39.42 |
| EBITDA | 98.67 | 178.15 | 109.45 | 72.76 |
| NET Worth | 334.86 | 268.94 | 149.19 | 93.79 |
| Reserves and Surplus | 320.23 | 254.31 | 134.56 | 79.15 |
| Total Borrowing | 70.99 | 70.13 | 82.21 | 89.84 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Supriya Lifescience RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Supriya Lifescience IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹16.92 | ₹16.39 |
| P/E Ratio (x) | 16.19 | 16.72 |
| Market Cap at Offer Price (₹ Cr) | ₹1,068.15 | ₹1,102.69 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹274 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹188.25 Cr of the issue is earmarked to named objects.
About the company
It was consistently the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021, with 45-50% and 60-65% of India's exports of those APIs. It also had 31% of India's Salbutamol Sulphate exports by volume in FY 2021.
From 1 April 2020 to 31 October 2021 it exported to 86 countries and 1,296 customers, including 346 distributors. Its plant in Maharashtra covers 23,806 sq. mts and has reactor capacity of 547 KL a day.
The IPO was Rs 700 crore, with Rs 200.00 crore of fresh issue and Rs 500.00 crore of offer for sale by the promoter Satish Waman Wagh. Rs 92.30 crore was planned for capital expenditure and Rs 60.00 crore for repaying borrowings.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
126 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
ICICI Securities
133 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Supriya Lifescience?
The current Grey Market Premium is ₹250, or 91% over the issue price.
What is the Supriya Lifescience IPO price band?
₹265 to ₹274, on a face value of ₹2.
When is the allotment?
The basis of allotment is 23 December 2021, with listing on 28 December 2021.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
